191 related articles for article (PubMed ID: 26243778)
1. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.
Wang W; Cortes JE; Lin P; Beaty MW; Ai D; Amin HM; McDonnell TJ; Ok CY; Kantarjian HM; Medeiros LJ; Hu S
Blood; 2015 Oct; 126(14):1699-706. PubMed ID: 26243778
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
[TBL] [Abstract][Full Text] [Related]
3. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
4. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Wang W; Cortes JE; Tang G; Khoury JD; Wang S; Bueso-Ramos CE; DiGiuseppe JA; Chen Z; Kantarjian HM; Medeiros LJ; Hu S
Blood; 2016 Jun; 127(22):2742-50. PubMed ID: 27006386
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
Johansson B; Fioretos T; Mitelman F
Acta Haematol; 2002; 107(2):76-94. PubMed ID: 11919388
[TBL] [Abstract][Full Text] [Related]
6. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
Crisan AM; Coriu D; Arion C; Colita A; Jardan C
J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
[TBL] [Abstract][Full Text] [Related]
7. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
[TBL] [Abstract][Full Text] [Related]
8. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review.
De Braekeleer M; Le Bris MJ; De Braekeleer E; Basinko A; Morel F; Douet-Guilbert N
Future Oncol; 2015; 11(11):1675-86. PubMed ID: 26043219
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.
Wang W; Tang G; Cortes JE; Liu H; Ai D; Yin CC; Li S; Khoury JD; Bueso-Ramos C; Medeiros LJ; Hu S
J Hematol Oncol; 2015 Apr; 8():32. PubMed ID: 25888368
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase inhibitors.
Theil KS; Cotta CV
Cancer Genet; 2014 May; 207(5):171-6. PubMed ID: 25027637
[TBL] [Abstract][Full Text] [Related]
12. Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis.
Lee EJ; Schiffer CA; Tomiyasu T; Testa JR
Leukemia; 1990 May; 4(5):350-3. PubMed ID: 2388480
[TBL] [Abstract][Full Text] [Related]
13. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors.
Ni H; Sun X; Xu Y; Lyle D; Petersen P; Zhao X; Drum H; You B; Liu D; Liu C; Jiang JG
Cancer Genet; 2019 Oct; 238():44-49. PubMed ID: 31425925
[TBL] [Abstract][Full Text] [Related]
15. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
Maloisel F; Uettwiller F; Laplace A; Lioure B; Herbrecht R; Mark M; Dufour P
Cancer Genet Cytogenet; 1999 Sep; 113(2):172-6. PubMed ID: 10484986
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic findings in adult acute leukemia and myeloproliferative disorders with an involvement of megakaryocyte lineage.
Ohyashiki K; Ohyashiki JH; Hojo H; Ohtaka M; Toyama K; Sugita K; Nakazawa S; Sugiura K; Nakazawa K; Nagasawa T
Cancer; 1990 Feb; 65(4):940-8. PubMed ID: 2297663
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
18. 3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Hu Z; Medeiros LJ; Wang W; Chen Z; Tang G; Hodjat P; Yang S; Fang L; Li Y; Verstovsek S; Hu S
Mod Pathol; 2017 Jul; 30(7):940-951. PubMed ID: 28338652
[TBL] [Abstract][Full Text] [Related]
19. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
20. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
